Aimmune Therapeutics, Inc. announced the appointment of Andrew Oxtoby as Chief Commercial Officer. Mr. Oxtoby, a proven pharmaceutical executive with two decades of experience in the healthcare and consumer products industries, will join Aimmune in the newly created role on January 22, 2019. Mr. Oxtoby joins Aimmune from Eli Lilly and Company, where he most recently had responsibility for Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, an innovative, patient-focused business unit, after having served as Vice President of U.S. Diabetes Sales.